Opposite Diastolic Effects Of Omecamtiv Mecarbil Versus Dobutamine And Ivabradine Co-Treatment In Pigs With Acute Ischemic Heart Failure

Acute ischemic cardiogenic shock is associated with poor prognosis, and the impact of inotropic support on diastolic function in this context is unclear. We assessed two suggested new inotropic strategies in a clinically relevant pig model of ischemic acute heart failure (AHF): treatment with the myosin activator omecamtiv mecarbil (OM) or dobutamine and ivabradine (D+I). Left ventricular (LV) ischemia was induced in anesthetized pigs by coronary microembolization (n=12). The animals then received OM (bolus 0.75mg/kg, followed by 0.5mg/kg per h) (n=6) or D+I (5g/kg per min + 0.29 +/- 0.16mg/kg) (n=6), respectively. Ischemia reduced the stroke volume (SV), despite the increased left atrial pressure associated with impaired LV early relaxation, systolic dilatation, and LV late diastolic stiffness. Both treatments improved systolic ejection, but only D+I increased the SV from 26 +/- 5 to 33 +/- 5mL. D+I enhanced LV early relaxation (Tau; from 45 +/- 11 to 29 +/- 4msec) and prolonged the diastolic time (DT) from 338 +/- 60 to 352 +/- 40msec. In contrast, OM prolonged Tau (42 +/- 5 to 62 +/- 10msec) and shortened the DT (from 326 +/- 68 to 248 +/- 84msec). Our data suggest that enhanced early relaxation by D+I improves LV pump function in postischemic acute heart failure. In contrast, OM worsened lusitropy in this model.